Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: This disclosure provides a potency assay for evaluating the potency of facilitating cells and/or alpha beta TCR+ T cells.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: This disclosure provides a potency assay for evaluating the potency of facilitating cells and/or alpha beta TCR+ T cells.

Abstract: Methods of expanding FCs or stem cells are provided herein, as are methods of screening for compounds that increase expression of DOCK2 or decrease expression of Arhgap18, either of which improves engraftment.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: Methods of expanding FCs or stem cells are provided herein, as are methods of screening for compounds that increase expression of DOCK2 or decrease expression of Arhgap18, either of which improves engraftment.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: This disclosure describes methods of screening for compounds that increase the number of p-preDCs and/or Tregs.

Abstract: The invention provides for methods of screening for compounds that increase the expression of P-selectin, SDF-1, and/or CXCR4 on facilitatory cells (FCs). The invention also provides for methods of screening for compounds that increase the level of p-predendritic cells (p-pre DC) without substantially decreasing the level of natural killer (NK) cells in a population of FCs. The invention further provides for methods of characterizing the facilitating capability of FCs by evaluating such cells for the amount of P-selectin, SDF-1, and/or CXCR4.

Abstract: The invention provides for methods for causing myeloid precursor cells in bone marrow to differentiate into dendritic cells, methods of screening for compounds that relieve a block in the development of mature myeloid progeny and/or that increase the population of HSA+/Ly6C+ cells in bone marrow, and methods of preventing or delaying an autoimmune disease such as diabetes.

Abstract: The present invention relates to the identification and use of facilitating cells that are critical for engraftment of purified “hematopoietic stem cells” (HSC), and more specifically this invention relates to two cell populations of CD8+ cells, that is, CD8+/TCR− “facilitating cells” (FC) which are critical to “hematopoietic stem cells” (HSC) survival and self-renewal, and CD8+/TCR+ cells which enhance the level of donor engraftment but do not promote long-term, durable engraftment. These two cell populations may have a wide range of applications, including but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.

Abstract: The primary focus of this the present invention is to disclose a minimal conditioning approach to establish mixed chimerism to induce tolerance in recipients having autoimmune disease. Engraftment is multifactorial. Both donor and host factors influence engraftment as independent but complementary variables. By optimizing first the donor factors that influence outcome and then defining the recipient factors that resist engraftment. Chimerisms in recipients with minimum morbidity can be achieved, thus allowing for the prevention or treatment of autoimmune disease.

Abstract: This invention provides a method of achieving a higher rate of allogeneic hematopoietic stem cell engraftment by either (i) matching the major histocompatibility complex class I K locus between donors and recipients or (ii) identifying how class I K on HSC interact with FC (CD8/33Kd receptor complex) works thus allowing one to bypass the need for FC. The MHC loci which are essential for curable engraftment of purified allogeneic HSC are identified by the methods of this invention. This invention further demonstrates that the MHC class I K molecule is essential for maintaining the self-renewal capability of purified HSC. Moreover, interaction between the HSC and FC via the MHC class I K molecule provides a regulatory function to promote engraftment and survival of allogeneic HSC.

Abstract: The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.